Retrospective Study on a Pediatric Status Epilepticus Pathway
Abstract number :
1.307
Submission category :
4. Clinical Epilepsy / 4C. Clinical Treatments
Year :
2025
Submission ID :
552
Source :
www.aesnet.org
Presentation date :
12/6/2025 12:00:00 AM
Published date :
Authors :
Presenting Author: Alex Manlapaz-Mann, DO – Montefiore Medical Center
Mauricio Borda, MD – Montefiore Medical Center
Cory Ransom, MD PhD – Montefiore Medical Center
Katherine Meurer, BS – Albert Einstein College of Medicine
Victor Ferastraoaru, MD – Montefiore Medical Center
Elissa Yozawitz, MD – Montefiore Medical Center
Daniel Lax, MD – Montefiore Medical Center
Rationale: Convulsive status epilepticus (CSE) requires rapid intervention to prevent . Fosphenytoin, levetiracetam and valproate were shown to be similarly effective for treatment of benzodiazepine-resistant status epilepticus in children.1 care with rapid drug access at our institution decreased time to second-line therapy.2 This follow-up study examines the use of second-line antiseizure medications (ASMs), i.e. first non-benzodiazepine agent, in pediatric benzodiazepine-resistant CSE, using the need for a third ASM as an indicator of failure of the second ASM.
Methods: We retrospectively reviewed 500 patient charts at the Children’s Hospital at Montefiore (CHAM) from July 2016 to June 2024. Patients under 21 years old with ICD codes for “seizure,” “status epilepticus” were screened. Charts were reviewed to confirm CSE, benzodiazepine administration, second ASM selection, and need for additional agents. Exclusions included non-convulsive or neonatal seizures, and deviations from the established CHAM treatment pathway.2additional ASM use following benzodiazepine administration were statistically significant.
Results: A total of 158 encounters met inclusion criteria; 123 met strict criteria for CSE, (4% female, median, range 7 months to 19 years). with or without ASM underdosing/nonadherence (34.6%), acute intracranial pathology infection (37.7%), febrile CSE (19.5%), chronic structural abnormalities (1.3%), and 6.9%). Levetiracetam was the most commonly used initial ASM overall, particularly in cases of nonadherence and intracranial pathology. The choice of second ASM did not significantly differ by etiology (p = 0.551). Most encounters did not require a third ASM. Levetiracetam was effective in 67%, fosphenytoin in 62.7%, valproic acid in 83.3% (p = 0.769). Logistic regression accounting for sex, age and etiology similarly showed no statistically significant difference. Among patients treated with levetiracetam, 33% required a third ASM—most often fosphenytoin (19.3%, <
Clinical Epilepsy